دورية أكاديمية
أعرض في EDS

Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.

التفاصيل البيبلوغرافية
العنوان: Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.
المؤلفون: July J; Department of Neurosurgery, Medical Faculty of Universitas Pelita Harapan, Neuroscience Centre of Siloam Hospital Lippo Village, Tangerang, Indonesia.; Mochtar Riady Institute for Nanotechnology and Medical Science group, Universitas Pelita Harapan, Lippo Village, Tangerang, Indonesia., Patricia D; Department of Pathology, Medical Faculty of Universitas Pelita Harapan, Neuroscience Centre of Siloam Hospital Lippo Village, Tangerang, Indonesia., Gunawan PY; Department of Neurology, Medical Faculty of Universitas Pelita Harapan, Neuroscience Centre of Siloam Hospital Lippo Village, Tangerang, Indonesia., Setiajaya H; Division of Neurosurgery, Department of Surgery, Rumah Sakit Pusat Angkatan Darat Gatot Subroto, Jakarta, Indonesia., Ginting TE; Mochtar Riady Institute for Nanotechnology and Medical Science group, Universitas Pelita Harapan, Lippo Village, Tangerang, Indonesia., Putra TP; Stemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia., Wuisan Z; Stemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia., Budhiarko D; Stemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia., Masykura N; Stemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia., Prayogi G; Stemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia., Utomo AR; Stemcell and Cancer Institute, PT Kalbe Farma Tbk, Jakarta, Indonesia., Tandean S; Department of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Haji Adam Malik General Hospital, Medan 20155, Medan, Indonesia., Loe ML; Department of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Haji Adam Malik General Hospital, Medan 20155, Medan, Indonesia.
المصدر: The Pan African medical journal [Pan Afr Med J] 2020 Aug 20; Vol. 36, pp. 309. Date of Electronic Publication: 2020 Aug 20 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet ISSN: 1937-8688 (Electronic) NLM ISO Abbreviation: Pan Afr Med J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Kampala, Uganda : African Field Epidemiology Network
مواضيع طبية MeSH: Astrocytoma/*pathology , B7-H1 Antigen/*genetics , DNA Modification Methylases/*genetics , DNA Repair Enzymes/*genetics , Glioblastoma/*pathology , Isocitrate Dehydrogenase/*genetics , Tumor Suppressor Proteins/*genetics, Adolescent ; Adult ; Aged ; Astrocytoma/genetics ; Astrocytoma/therapy ; DNA Methylation ; Female ; Glioblastoma/genetics ; Glioblastoma/therapy ; Humans ; Male ; Middle Aged ; Mutation ; Prognosis ; Promoter Regions, Genetic/genetics ; Retrospective Studies ; Survival Rate ; Young Adult
مستخلص: Introduction: the objective was to evaluate the impact of IDH1 R132H mutation, MGMT methylation and PD-L1 expression in high grade glioma that received standard therapy (surgery, radiation and chemotherapy) to overall survival (OS).
Methods: this is a retrospective study of 35 high grade glioma cases. Genotyping of IDH1 gene alteration on the mutation hotspot R132 (Sanger sequencing method with Applied Biosystems 3500 Genetic Analyzer), EZ DNA Methylation-Gold kit (Zymo Research) is used to study the methylation, Cell line BT549 (ATCC HTB-122) and HCT-116 (ATCC CCL-247) were used as unmethylated control and partially methylated control respectively. Anti-human PD-L1 antibody clone E1L3N ® from Cell Signalling Technology (USA) and Rabbit XP ® were used to see PDL-1 expression.
Results: anaplastic astrocytoma cases had more MGMT promoter methylation (50%) than glioblastoma multiforme (GBM) (20%), more IDH1 R132H mutation (42%) than GBM (4.3%). Immunohistochemistry tumor proportion score method (TPS) identified 17% and 8.7% were PD-L1 positive in AA and GBM groups, respectively. Cases with IDH1 R132H mutation and MGMT methylation still showed better OS although with high PD-L1 expression.
Conclusion: IDH1 R132H mutation and MGMT methylation were good prognostic markers. High expression of PD-L1 apparently might not indicate poor overall survival in the presence of IDH1 R132 mutation and MGMT methylation.
Competing Interests: The authors declare no competing interests.
(Copyright: Julius July et al.)
References: Oncogene. 2018 Apr;37(15):1949-1960. (PMID: 29367755)
Radiol Oncol. 2016 Nov 10;50(4):394-401. (PMID: 27904447)
Clinics (Sao Paulo). 2011;66(10):1747-55. (PMID: 22012047)
Neuro Oncol. 2016 Feb;18(2):195-205. (PMID: 26323609)
Curr Treat Options Oncol. 2001 Dec;2(6):495-506. (PMID: 12057095)
Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):301-311. (PMID: 28592714)
Neurooncol Pract. 2014 Dec;1(4):166-171. (PMID: 26034628)
Neuro Oncol. 2016 Oct;18(10):1357-66. (PMID: 27370400)
Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S2-8. (PMID: 27668386)
Clin Transl Oncol. 2018 Jan;20(1):22-28. (PMID: 29086250)
Neurosurg Focus. 2015 Jan;38(1):E6. (PMID: 25552286)
Brain Sci. 2018 Jan 16;8(1):. (PMID: 29337870)
Brain. 2007 Oct;130(Pt 10):2596-606. (PMID: 17785346)
Anticancer Res. 2018 Oct;38(10):5903-5907. (PMID: 30275217)
Prog Nucleic Acid Res Mol Biol. 1995;51:167-223. (PMID: 7659775)
Neuro Oncol. 2015 Jul;17(7):999-1006. (PMID: 25688120)
N Engl J Med. 2000 Nov 9;343(19):1350-4. (PMID: 11070098)
J Thorac Cardiovasc Surg. 2018 Jan;155(1):382-392.e1. (PMID: 28711324)
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150. (PMID: 28815663)
J Thorac Dis. 2017 Aug;9(8):2579-2586. (PMID: 28932565)
Acta Neuropathol. 2008 Dec;116(6):597-602. (PMID: 18985363)
Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441)
Onco Targets Ther. 2018 Aug 08;11:4673-4683. (PMID: 30122958)
Oncol Lett. 2017 Jul;14(1):229-233. (PMID: 28693158)
Cancer Discov. 2018 Sep;8(9):1069-1086. (PMID: 30115704)
Oncotarget. 2017 Jun 27;8(26):42214-42225. (PMID: 28178682)
Neuro Oncol. 2015 Aug;17(8):1064-75. (PMID: 25355681)
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101. (PMID: 24782454)
ACS Med Chem Lett. 2012 Sep 17;3(10):850-5. (PMID: 24900389)
EMBO Mol Med. 2014 Oct 13;6(11):1359-70. (PMID: 25312641)
Mol Cancer. 2016 Aug 24;15(1):55. (PMID: 27552968)
Clin Cancer Res. 2015 May 1;21(9):2057-64. (PMID: 25655102)
J Clin Invest. 2007 May;117(5):1137-46. (PMID: 17476343)
Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931)
N Engl J Med. 2009 Feb 19;360(8):765-73. (PMID: 19228619)
Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S68-77. (PMID: 25722935)
فهرسة مساهمة: Keywords: IDH1 mutation; MGMT methylation; PD-L1; anaplastic astrocytoma; glioblastoma multiforme
المشرفين على المادة: 0 (B7-H1 Antigen)
0 (CD274 protein, human)
0 (Tumor Suppressor Proteins)
EC 1.1.1.41 (Isocitrate Dehydrogenase)
EC 1.1.1.42. (IDH1 protein, human)
EC 2.1.1.- (DNA Modification Methylases)
EC 2.1.1.63 (MGMT protein, human)
EC 6.5.1.- (DNA Repair Enzymes)
تواريخ الأحداث: Date Created: 20201207 Date Completed: 20210113 Latest Revision: 20231112
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC7687483
DOI: 10.11604/pamj.2020.36.309.24831
PMID: 33282092
قاعدة البيانات: MEDLINE
الوصف
تدمد:1937-8688
DOI:10.11604/pamj.2020.36.309.24831